NCT02559778 2026-02-20
PEDS-PLAN
Milton S. Hershey Medical Center
Phase 2 Recruiting
Clinical Trials
37 trialsNCT06145633 2026-01-28
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Fred Hutchinson Cancer Center
Phase 2 Recruiting
NCT07261241 2025-12-03
NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab
New Approaches to Neuroblastoma Therapy Consortium
Phase 2 Not yet recruiting
NCT05608369 2025-04-04
HPV
Case Comprehensive Cancer Center
Phase 2 Withdrawn
NCT04357873 2025-02-19
PEVOsq
UNICANCER
Phase 2 Completed
NCT04220008 2024-01-12
Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT02316340 2024-01-05
Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT04190056 2023-08-31
Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer
University of California, San Francisco
Phase 2 Terminated
NCT02035137 2022-06-08
N2011-01
New Approaches to Neuroblastoma Therapy Consortium
Phase 2 Completed
NCT02395627 2020-07-07
Reversing Therapy Resistance With Epigenetic-Immune Modification
University of California, San Francisco
Phase 2 Terminated
NCT00948064 2020-02-24
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00798720 2019-12-13
Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer
University of Wisconsin, Madison
Phase 2 Completed
NCT00958074 2018-10-18
Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma
University of Washington
Phase 2 Terminated
NCT00918489 2018-10-17
SAHA-I
Heidelberg University
Phase 2 Completed
NCT01790568 2018-08-13
Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT00720876 2018-08-07
Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 2 Completed
NCT02419755 2018-03-07
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT00818649 2017-12-28
Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00882206 2017-12-28
Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT01312818 2017-12-28
Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00764517 2017-12-11
Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma
OHSU Knight Cancer Institute
Phase 2 Completed
NCT00837174 2017-09-19
COMBOSTAT
The Methodist Hospital Research Institute
Phase 2 Withdrawn
NCT00673153 2017-06-01
Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT01738646 2017-03-06
Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients
Duke University
Phase 2 Completed
NCT01501370 2016-05-10
ZLd_Ld
University of Turin, Italy
Phase 2 Withdrawn
NCT01500538 2016-02-15
VEIL
Peter MacCallum Cancer Centre, Australia
Phase 2 Terminated
NCT00656617 2015-03-09
Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00365599 2014-11-21
Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT02114502 2014-07-11
Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00942266 2014-06-23
Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment
Roswell Park Cancer Institute
Phase 2 Completed
NCT01600742 2014-01-09
Vorinostat and Concurrent Whole Brain Radiotherapy for Brain Metastasis
National Taiwan University Hospital
Phase 2 Terminated
NCT01194427 2013-05-17
A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00810576 2012-08-07
Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01492881 2012-05-11
Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Withdrawn
NCT00866762 2011-12-12
A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia
Copenhagen University Hospital at Herlev
Phase 2 Unknown
NCT01039363 2009-12-25
Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia
Samsung Medical Center
Phase 2 Unknown
NCT00772798 2008-10-15
A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer
Herlev Hospital
Phase 2 Unknown